<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690908</url>
  </required_header>
  <id_info>
    <org_study_id>NI_2016_1_ALR</org_study_id>
    <nct_id>NCT03690908</nct_id>
  </id_info>
  <brief_title>Infraorbital Nerve Involvement on Magnetic Resonance Imaging in IgG4-related Ophthalmic Disease</brief_title>
  <acronym>RetroG4</acronym>
  <official_title>Infraorbital Nerve Involvement on Magnetic Resonance Imaging in European Patients With IgG4-related Ophthalmic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infraorbital nerve enlargement (IONE) on magnetic resonance imaging is known to be a possible
      consequence of IgG4-related ophthalmic disease. However this imaging sign can also be found
      in other conditions causing orbital inflammation. This study aims at comparing the frequency
      of IONE in patients suffering from IgG4-related ophthalmic disease (IgG4-ROD) versus patients
      suffering from non-IgG4-related ophthalmic disease (non-IgG4-ROD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">November 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with infraorbital nerve involvement in magnetic resonance imaging</measure>
    <time_frame>Within 2 weeks after the first consultation for orbital inflammation</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>IgG4-related Disease</condition>
  <condition>Orbital Infections, Inflammations and Irritations</condition>
  <arm_group>
    <arm_group_label>IgG4-related orbital inflammation</arm_group_label>
    <description>patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non IgG4-related orbital inflammation</arm_group_label>
    <description>patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention (descriptive study)</intervention_name>
    <description>no intervention (descriptive study)</description>
    <arm_group_label>IgG4-related orbital inflammation</arm_group_label>
    <arm_group_label>non IgG4-related orbital inflammation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients suffering from non-thyroid, non-lymphoma related orbital inflammation
        treated in Fondation Rothschild (tertiary ophtalmology facility, Paris, France) from
        January 2006 through April 2015.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patient aged 18 and older treated in Fondation Rothschild (tertiary ophthalmology
             facility, Paris, France) from January 2006 through April 2015

          -  Presence of a clinical orbital inflammation: mass/swelling, pain, exophthalmos, visual
             loss, ptosis, or diplopia.

          -  The presence of at least one pretherapeutic MRI confirming the inflammation of one or
             more orbital structures: the lacrimal gland, fat, muscles, or infraorbital nerve. The
             mandatory minimal MRI protocol include the following sequences: T1- and T2-weighted
             MRI image, in the transverse and coronal plane, and a fat-suppressed T1-weighted image
             in the coronal plane obtained after intravenous administration of a gadolinium
             chelate.

          -  Completion of at least one orbital biopsy with a pathologic examination and an
             immunohistochemical screen for IgG4.

        Exclusion criteria :

          -  Clinical and biological signs of thyroid-associated orbitopathy

          -  Histologically proven lymphoma

          -  Pretherapeutic MRI that is insufficient for an adequate interpretation

          -  Absence of IgG4 testing in the pathology examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rotchschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G4-Related Disease</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

